T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Lam Research
LRCX
$429B
| $501M | 0.05% |
6,970,220
+3,357,680
| +93% | +$210M |
|
352
Terreno Realty
TRNO
$7.5B
| $499M | 0.04% |
5,850,239
+107,696
| +2% | +$8.11M |
|
353
Lowe's Companies
LOW
$122B
| $497M | 0.04% |
1,924,311
-31,349
| -2% | -$7.45M |
|
354
Alkermes
ALKS
$8.3B
| $496M | 0.04% |
21,343,581
+77,340
| +0.4% | +$2.03M |
|
355
Pinnacle Financial Partners Inc
PNFP
$16.2B
| $491M | 0.04% |
5,142,843
-311,918
| -6% | -$30.5M |
|
356
Cadence Design Systems
CDNS
$89.4B
| $488M | 0.04% |
2,621,209
+404,033
| +18% | +$70.4M |
|
357
Halliburton
HAL
$27.4B
| $488M | 0.04% |
21,346,049
+2,410,978
| +13% | +$57.1M |
|
|
BPMC
358
DELISTED
Blueprint Medicines
BPMC
| $487M | 0.04% |
4,550,539
+178,711
| +4% | +$18.7M |
|
359
Papa John's
PZZA
$812M
| $484M | 0.04% |
3,626,420
-94,925
| -3% | -$12.1M |
|
|
P
360
Everpure Inc
P
$38.7B
| $482M | 0.04% |
14,817,260
-3,260,758
| -18% | -$94.6M |
|
|
XLNX
361
DELISTED
Xilinx Inc
XLNX
| $481M | 0.04% |
2,270,388
-2,325,122
| -51% | -$459M |
|
362
FIVE9
FIVN
$2.38B
| $481M | 0.04% |
3,505,400
-820,127
| -19% | -$121M |
|
363
Armstrong World Industries
AWI
$7.73B
| $472M | 0.04% |
4,066,193
-757,943
| -16% | -$81.8M |
|
|
SPLK
364
DELISTED
Splunk Inc
SPLK
| $468M | 0.04% |
4,041,325
-5,692,175
| -58% | -$795M |
|
365
Live Oak Bancshares
LOB
$1.99B
| $468M | 0.04% |
5,357,451
-144,020
| -3% | -$12M |
|
|
SOLN
366
DELISTED
The Southern Company
SOLN
| $466M | 0.04% |
8,725,876
-65,535
| -0.7% | -$3.39M |
|
367
Idexx Laboratories
IDXX
$44.2B
| $460M | 0.04% |
698,848
-20,055
| -3% | -$12.6M |
|
368
Pinduoduo
PDD
$120B
| $457M | 0.04% |
7,841,607
-3,401,153
| -30% | -$268M |
|
369
RH
RH
$3.42B
| $455M | 0.04% |
849,030
-95,263
| -10% | -$58.6M |
|
|
BNY
370
Bank of New York Mellon
BNY
$110B
| $451M | 0.04% |
7,765,450
-1,169,139
| -13% | -$67.2M |
|
371
Adobe
ADBE
$103B
| $438M | 0.04% |
773,225
-27,365
| -3% | -$17.1M |
|
372
Canadian Pacific Kansas City
CP
$82.4B
| $432M | 0.04% |
6,004,923
+1,616,533
| +37% | +$118M |
|
373
Popular Inc
BPOP
$11.3B
| $428M | 0.04% |
5,221,199
-48,759
| -0.9% | -$3.96M |
|
|
OCDX
374
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $427M | 0.04% |
19,981,658
+115,758
| +0.6% | +$2.28M |
|
|
PSB
375
DELISTED
PS Business Parks, Inc.
PSB
| $424M | 0.04% |
2,299,797
-40,140
| -2% | -$7.06M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.